KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Cash Flow (2016 - 2025)

Biogen has reported Net Cash Flow over the past 17 years, most recently at -$856.8 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$856.8 million for Q4 2025, down 214.21% from a year ago — trailing twelve months through Dec 2025 was $531.6 million (down 61.83% YoY), and the annual figure for FY2025 was $531.6 million, down 61.83%.
  • Net Cash Flow for Q4 2025 was -$856.8 million at Biogen, down from $1.1 billion in the prior quarter.
  • Over the last five years, Net Cash Flow for BIIB hit a ceiling of $1.1 billion in Q3 2025 and a floor of -$1.3 billion in Q4 2023.
  • Median Net Cash Flow over the past 5 years was -$16.6 million (2021), compared with a mean of $86.2 million.
  • Peak annual rise in Net Cash Flow hit 718.59% in 2022, while the deepest fall reached 522.92% in 2022.
  • Biogen's Net Cash Flow stood at $735.4 million in 2021, then crashed by 143.99% to -$323.5 million in 2022, then crashed by 297.5% to -$1.3 billion in 2023, then surged by 158.34% to $750.2 million in 2024, then tumbled by 214.21% to -$856.8 million in 2025.
  • The last three reported values for Net Cash Flow were -$856.8 million (Q4 2025), $1.1 billion (Q3 2025), and $92.2 million (Q2 2025) per Business Quant data.